IMNM Stock — Immunome Inc.: Cash, EV, Pipeline

Share price

$23.97

Market cap

$2,722.5M

Cash

$520.0M

Enterprise value

$2,202.5M

Balance sheet

Cash	$520.0M
Debt	$0.0M
Net cash	$520.0M
Enterprise value	$2,202.5M
Basic shares	113.4M shares
Fully diluted shares	131.9M shares
Fully diluted market cap	$3,161.4M
Cash per share	$4.59

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading IMNM daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jun 12 - Jul 24	IM-1021	Phase 1	Solid Malignancies; Hematologic Malignancies	—
Feb 12 - Mar 26	IM-1617	Phase 1	Colorectal Cancer; Non-Small Cell Lung Cancer; Breast Cancer	—
Jan 12 - Feb 23	177Lu-IM-3050	Early Phase 1	Solid Malignancies	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Varegacestat

Phase 3 · Active Modality: oral gamma secretase inhibitor

Aliases AL102

Target gamma secretase

Partnerships Ayala Pharmaceuticals (asset acquisition, March 2024); Bristol-Myers Squibb (license)

Indications

desmoid tumors (Phase 3)

Catalysts

— April 28, 2027
— end of 2026

Status note NDA submitted April 2026 and accepted July 2026; Phase 3 RINGSIDE Part B completed; no discontinuation disclosed.

IM-1021

Phase 1 · Active Modality: antibody-drug conjugate (ROR1, HC74 TOP1 inhibitor payload)

Target ROR1

Indications

solid tumors (Phase 1)
B-cell lymphoma (Phase 1)

Catalysts

— 2026

Status note Phase 1 ongoing; no discontinuation disclosed.

IM-1617

Phase 1 · Active Modality: antibody-drug conjugate

Indications

solid tumors (colorectal, NSCLC, breast, ovarian) (Phase 1)

Status note First participant dosed June 2026; target is an undisclosed receptor tyrosine kinase; no discontinuation disclosed.

IM-3050

Phase 1 · Active Modality: FAP-targeted lutetium-177 radioligand therapy

Target FAP

Indications

FAP-expressing solid tumors (Phase 1)

Status note First participant dosed July 2026; no discontinuation disclosed.

IM-1340

Preclinical · Active Modality: antibody-drug conjugate

Indications

neuroendocrine tumors (Preclinical)
lung and prostate carcinomas (Preclinical)

Catalysts

— mid-2026

Status note IND-enabling work ongoing; IND submission expected mid-2026 per filing; no discontinuation disclosed.

IM-1335

Preclinical · Active Modality: antibody-drug conjugate

Indications

solid tumors (Preclinical)

Catalysts

— late 2026

Status note IND-enabling work ongoing; shares target with a discontinued competitor ADC; no discontinuation disclosed.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	AL102
Lead indication	Desmoid
Lead phase	Phase 3
Active trials	5

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04871282	Phase 3	Active, not recruiting	Sponsor	IMNM	—	Desmoid; Desmoid Tumor	—
NCT06823167	Phase 1	Recruiting	Sponsor	IMNM	—	Solid Malignancies; Hematologic Malignancies	—
NCT07578571	Phase 1	Recruiting	Sponsor	IMNM	—	Colorectal Cancer; Non-Small Cell Lung Cancer; Breast Cancer	—
NCT07610005	Phase 1	Recruiting	Sponsor	IMNM	—	Healthy	—
NCT07505771	Early Phase 1	Recruiting	Sponsor	IMNM	—	Solid Malignancies	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Immunome, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Ikarian Capital	60,000	+60,000	0.21%	2026-08-14
Baker Bros. Advisors	55,306	+55,306	0.01%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

IMNM — Immunome Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders